Wyeth CEO: FDA creating monopoly meds

U.S. drug regulators aren't playing fair, says outgoing Wyeth CEO Bob Essner. New meds that should be allowed on the market--because they're safe and effective--are blocked if they're not demonstrably better than existing products. That effectively hands monopoly status to the first company to market with a given type of drug, Essner says.

Essner is echoing concerns raised by Novartis CEO Daniel Vasella (photo), who questioned the FDA's right to ask whether new drugs are better than those already being sold. Both companies suffered painful denials recently, Wyeth for bifeprunox, a schizophrenia treatment, and Novartis for Prexige, a painkiller.

- check out the report from the Financial Times
- read this interview for more

Related Articles:
New drug approval lags in 2007. Report
FDA quick to reject drugs as it gets more cautious. Report
Industry exec says FDA approval process too strict. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.